Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).

Yin Y, Ma J, Liu D, Duan W, Cheng Z, Jiang H, Zhang Y, Wu G, Zhuang H, Gu W, Mu Y

Med (New York, N.Y.)15 Jun 2026

PMID42296968DOI10.1016/j.medj.2026.101183PepBankPUB-42296968

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with early type 2 diabetes, tirzepatide 5 mg reduced HbA1c more than placebo at week 40 (-2.17% vs -0.13%; difference -2.04%).
In plain wordsIn Chinese adults with early type 2 diabetes, tirzepatide 5 mg lowered blood sugar (HbA1c) much more than placebo at week 40.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline to week 40, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.17%
tirzepatide 5 mg
HbA1c change
−0.13%
placebo
Treatment difference vs placebo
−2.04%
5 mg
Source sentences
Summary
the least-squares mean reductions in HbA1c from baseline to week 40 were significantly greater with 5, 10, and 15 mg tirzepatide than with placebo (-2.17%, -2.06%, and -2.15% vs. -0.13%
3 context sentences(design, population, supporting numbers)
Summary · context
with treatment differences vs. placebo of -2.04% [95% confidence interval (CI): -2.46, -1.63], -1.93% [95% CI: -2.35, -1.51], and -2.02% [95% CI: -2.44, -1.60], respectively; p < 0.001 for all comparisons).
Summary · context
The primary endpoint was the mean change from baseline in hemoglobin A1c (HbA1c) at week 40.
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696801
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with early type 2 diabetes, tirzepatide 10 mg reduced HbA1c more than placebo at week 40 (-2.06% vs -0.13%; difference -1.93%).
In plain wordsIn Chinese adults with early type 2 diabetes, tirzepatide 10 mg lowered blood sugar (HbA1c) much more than placebo at week 40.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline to week 40, tirzepatide 10 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.06%
tirzepatide 10 mg
HbA1c change
−0.13%
placebo
Treatment difference vs placebo
−1.93%
10 mg
Source sentences
Summary
the least-squares mean reductions in HbA1c from baseline to week 40 were significantly greater with 5, 10, and 15 mg tirzepatide than with placebo (-2.17%, -2.06%, and -2.15% vs. -0.13%
3 context sentences(design, population, supporting numbers)
Summary · context
with treatment differences vs. placebo of -2.04% [95% confidence interval (CI): -2.46, -1.63], -1.93% [95% CI: -2.35, -1.51], and -2.02% [95% CI: -2.44, -1.60], respectively; p < 0.001 for all comparisons).
Summary · context
The primary endpoint was the mean change from baseline in hemoglobin A1c (HbA1c) at week 40.
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696802
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with early type 2 diabetes, tirzepatide 15 mg reduced HbA1c more than placebo at week 40 (-2.15% vs -0.13%; difference -2.02%).
In plain wordsIn Chinese adults with early type 2 diabetes, tirzepatide 15 mg lowered blood sugar (HbA1c) much more than placebo at week 40.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline to week 40, tirzepatide 15 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.15%
tirzepatide 15 mg
HbA1c change
−0.13%
placebo
Treatment difference vs placebo
−2.02%
15 mg
Source sentences
Summary
the least-squares mean reductions in HbA1c from baseline to week 40 were significantly greater with 5, 10, and 15 mg tirzepatide than with placebo (-2.17%, -2.06%, and -2.15% vs. -0.13%
3 context sentences(design, population, supporting numbers)
Summary · context
with treatment differences vs. placebo of -2.04% [95% confidence interval (CI): -2.46, -1.63], -1.93% [95% CI: -2.35, -1.51], and -2.02% [95% CI: -2.44, -1.60], respectively; p < 0.001 for all comparisons).
Summary · context
The primary endpoint was the mean change from baseline in hemoglobin A1c (HbA1c) at week 40.
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696803
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with early type 2 diabetes, tirzepatide 5 mg reduced body weight more than placebo at week 40 (-6.0 vs -1.0 kg).
In plain wordsIn Chinese adults with early type 2 diabetes, tirzepatide 5 mg led to more weight loss than placebo at week 40.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change from baseline to week 40, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg · 40 weeksAs given in this study (human).
Measurements
Body weight change
−6 kg
tirzepatide 5 mg
Body weight change
−1 kg
placebo
Source sentences
Summary
The least-squares mean reductions in body weight from baseline to week 40 were significantly greater with 5, 10, and 15 mg tirzepatide vs. placebo (-6.0, -6.1, and -9.7 vs. -1.0 kg, respectively; p < 0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696804
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with early type 2 diabetes, tirzepatide 10 mg reduced body weight more than placebo at week 40 (-6.1 vs -1.0 kg).
In plain wordsIn Chinese adults with early type 2 diabetes, tirzepatide 10 mg led to more weight loss than placebo at week 40.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change from baseline to week 40, tirzepatide 10 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg · 40 weeksAs given in this study (human).
Measurements
Body weight change
−6.1 kg
tirzepatide 10 mg
Body weight change
−1 kg
placebo
Source sentences
Summary
The least-squares mean reductions in body weight from baseline to week 40 were significantly greater with 5, 10, and 15 mg tirzepatide vs. placebo (-6.0, -6.1, and -9.7 vs. -1.0 kg, respectively; p < 0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696805
06HumanRandomized controlled trialEfficacy outcome
In Chinese adults with early type 2 diabetes, tirzepatide 15 mg reduced body weight more than placebo at week 40 (-9.7 vs -1.0 kg).
In plain wordsIn Chinese adults with early type 2 diabetes, tirzepatide 15 mg led to more weight loss than placebo at week 40.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change from baseline to week 40, tirzepatide 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · 40 weeksAs given in this study (human).
Measurements
Body weight change
−9.7 kg
tirzepatide 15 mg
Body weight change
−1 kg
placebo
Source sentences
Summary
The least-squares mean reductions in body weight from baseline to week 40 were significantly greater with 5, 10, and 15 mg tirzepatide vs. placebo (-6.0, -6.1, and -9.7 vs. -1.0 kg, respectively; p < 0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696806
07HumanRandomized controlled trialSafety outcome
In Chinese adults with early type 2 diabetes, the most common treatment-emergent adverse events in the tirzepatide groups were gastrointestinal.
In plain wordsIn Chinese adults with early type 2 diabetes, the most common side effects of tirzepatide were stomach and bowel problems.
Peptide
Tirzepatide
Outcome
Not applicableTreatment-emergent adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg · 40 weeksAs given in this study (human).
Source sentences
Summary
In the tirzepatide groups, the most common treatment-emergent adverse events were gastrointestinal related
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696807
08HumanRandomized controlled trialSafety outcome
In Chinese adults with early type 2 diabetes, tirzepatide groups had no clinically significant (<54 mg/dL) or severe hypoglycemia.
In plain wordsIn Chinese adults with early type 2 diabetes, no one on tirzepatide had clinically significant or severe low blood sugar.
Peptide
Tirzepatide
Outcome
No significant changeClinically significant or severe hypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
5, 10 or 15 mg · 40 weeksAs given in this study (human).
Source sentences
Summary
there was no clinically significant (<54 mg/dL) or severe hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-4229696808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05963022

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Eli Lilly and Companyn = 20621 Aug 2023 to 9 Oct 2024

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 21 Oct 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.